Ani Pharmaceuticals reported $56.28M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Aerie Pharmaceuticals AERI:US USD 54.09M 14.65M
Ani Pharmaceuticals ANIP:US USD 56.28M 7.1M
Aurora Cannabis Inc ACB:CN CAD 369.28M 68.53M
Canopy Growth Corp WEED:CN CAD 318.43M 6.29M
Depomed DEPO:US USD 64.83M 12.56M
Eli Lilly And LLY:US USD 2.62B 5.5M
Emergent Biosolutions EBS:US USD 240.9M 117.2M
Endo International Ordinary Shares ENDP:US USD 1.05B 137.68M
Heron Therapeutics HRTX:US USD 50.44M 1.83M
Hikma Pharmaceutical HIK:LN USD 23M 1000K
Knight Therapeutics Inc GUD:CN CAD 4.27M 5.53M
Lannett LCI:US USD 77.92M 9.94M
Nektar Therapeutics NKTR:US USD 105.76M 28.21M
Novartis NVS:US USD 8.73B 5.1B
Omeros OMER:US USD 145.53M 131.4M
Perrigo Ordinary Shares PRGO:US USD 468.7M 16.6M
Teva Pharmaceutical TEVA:IT USD 2.22B 167M
Teva Pharmaceutical Industries TEVA:US USD 2.22B 167M